Search
Ecraprost
go.drugbank.com/drugs/DB16148InvestigationalEcraprost is under investigation in clinical trial NCT00059657 (Efficacy/safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial Disease).
Erfonrilimab
go.drugbank.com/drugs/DB17446InvestigationalErfonrilimab is a bispecific monoclonal antibody directed against both the programmed cell death-1 ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4).
XmAb24306
go.drugbank.com/drugs/DB17526InvestigationalXmAb24306 is an investigational cancer immunotherapy. It is a heterodimeric interleukin (IL)-15/IL-15-receptor alpha (IL-15Ra) complex fused to a bispecific Fc domain.
Enarodustat
go.drugbank.com/drugs/DB14985InvestigationalEnarodustat is under investigation in clinical trial NCT02581124 (Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease).
Categories: Heterocyclic Compounds, 1-RingGremubamab
go.drugbank.com/drugs/DB15014InvestigationalGremubamab is under investigation in clinical trial NCT02255760 (Phase 1 Randomized Double-blind Placebo Controlled Study to Evaluate Safety and PK of MEDI3902 in Healthy Adults).
Ponezumab
go.drugbank.com/drugs/DB15135InvestigationalPonezumab is under investigation in clinical trial NCT00607308 (A Phase I, Single Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease).
Dubermatinib
go.drugbank.com/drugs/DB15187InvestigationalDubermatinib is under investigation in clinical trial NCT03572634 (Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL).
Categories: Heterocyclic Compounds, 1-RingReldesemtiv
go.drugbank.com/drugs/DB15256InvestigationalReldesemtiv is under investigation in clinical trial NCT03160898 (A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)).
Categories: Heterocyclic Compounds, 1-RingLazucirnon
go.drugbank.com/drugs/DB15269InvestigationalALK-4290 is under investigation in clinical trial NCT03558061 (Evaluate the Effects and Safety of ALK4290 in Patients With Newly Diagnosed Wet Age-Related Macular Degeneration).
Lutetium Lu 177-DTPA-omburtamab
go.drugbank.com/drugs/DB31015InvestigationalLutetium Lu 177-DTPA-omburtamab is a radioimmunoconjugate made up of [omburtamab] conjugated with lutetium Lu 177 via the chelating agent of diethylenetriaminepentaacetic acid (DTPA).[L54566]